Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    AGBA

    MCap

    USD77m

    Last close

    USD1.03

    ▲ 0.63 (157.50%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    Sareum Holdings

    MCap

    GBP28m

    Last close

    GBP0.27

    ▲ 6.25 (30.49%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

OSE Immunotherapeutics (PAR: OSE)

Last close As at 18/04/2024

EUR5.00

▲ 0.13 (2.56%)

Market capitalisation

EUR109m

OSE Immunotherapeutics (OSE) is based in Nantes and Paris in France and is listed on the Euronext Paris exchange. It is developing immunotherapies for the treatment of solid tumours and autoimmune diseases and has established several partnerships with large pharma companies.

OSE has products in development for both immunoncology and immuno-inflammation indications. As a result, the R&D pipeline is diversified and the outlook does not depend on developments in any specific subsector.

Latest Insights

View More

Healthcare | Flash note

OSE Immunotherapeutics — AbbVie deal clears antitrust hurdle

Healthcare | Flash note

OSE Immunotherapeutics — Funding accelerates Tedopi clinical development

Healthcare | Update

OSE Immunotherapeutics — Pipeline momentum builds into FY24

Healthcare | Flash note

OSE Immunotherapeutics — One step closer to key data readouts
OSE-Immunotherapeutics_resized
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Dominique Costantini

    Chairman

  • Nicolas Poirier

    CEO

Balance Sheet

Forecast net cash (€m)

5.4

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 2.9 40.4 0.1
Relative 4.2 30.1 (5.2)
52 week high/low €6.2/€2.7

Financials

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its global licence and collaboration agreement for its pre-clinical asset OSE-230, a novel monoclonal antibody being developed for the treatment of chronic and severe inflammation. OSE is also entitled to receive up to US$665m in incremental (milestone) payments as part of the deal.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2022A 18.3 (15.0) (18.0) (97.28) N/A N/A
2023A 2.2 (19.6) (23.2) (118.70) N/A N/A
2024E 56.9 28.6 25.3 114.54 4.4 4.4
2025E 65.5 36.9 33.7 149.02 3.4 3.4

Research

Flash note

Healthcare

OSE Immunotherapeutics — Funding accelerates Tedopi clinical development

Update

Healthcare

OSE Immunotherapeutics — Pipeline momentum builds into FY24

Healthcare

Flash note

OSE Immunotherapeutics — AbbVie deal clears antitrust hurdle
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free